Table 1. Clinical features of MCL... | American Society of Hematology

Table 1.

Clinical features of MCL patients, including distributions between subsets

Parameter	All MCL n = 110	V_H gene mutation status		V_H gene use
Parameter	All MCL n = 110	Mutated MCL n = 18	Unmutated MCL n = 92	V_H3-21⁺MCL n = 21	MCL without V_H3-21 n = 89
Blastoid morphology	26 of 110	3 of 18	23 of 92	8 of 21	18 of 89
Stage III–IV	93 of 102	14 of 18	79 of 84	20 of 20	73 of 82
IPI score 3-5	50 of 89	7 of 14	43 of 75	11 of 19	39 of 70
Nodal involvement	100 of 106	18 of 18	82 of 88	20 of 20	80 of 86
Leukemic disease	32 of 102	5 of 16	27 of 86	5 of 20	27 of 82
Splenomegaly	46 of 108	6 of 18	40 of 90	11 of 21	35 of 87
ASCT^*	19 of 106	3 of 18	16 of 88	8 of 21^†	11 of 85^†

Parameter	All MCL n = 110	V_H gene mutation status		V_H gene use
Parameter	All MCL n = 110	Mutated MCL n = 18	Unmutated MCL n = 92	V_H3-21⁺MCL n = 21	MCL without V_H3-21 n = 89
Blastoid morphology	26 of 110	3 of 18	23 of 92	8 of 21	18 of 89
Stage III–IV	93 of 102	14 of 18	79 of 84	20 of 20	73 of 82
IPI score 3-5	50 of 89	7 of 14	43 of 75	11 of 19	39 of 70
Nodal involvement	100 of 106	18 of 18	82 of 88	20 of 20	80 of 86
Leukemic disease	32 of 102	5 of 16	27 of 86	5 of 20	27 of 82
Splenomegaly	46 of 108	6 of 18	40 of 90	11 of 21	35 of 87
ASCT^*	19 of 106	3 of 18	16 of 88	8 of 21^†	11 of 85^†

High-dose chemotherapy and ASCT.

ASCT at age 65 or younger: 8 of 12 V_H3-21⁺patients versus 10 of 33 of the remaining patients with MCL.